As for details, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma and the total numbers of TCL are constantly increasing in both countries. Conclusion In conclusion, we showed the marked difference in the incidence and the trend of hematologic malignancies between Japan and the US. The ...
while multiple myeloma is a blood cancer that develops in plasma cells, which are white blood cells that originate from B cells in response to infection. Thus, this is the key difference between CLL and multiple myeloma. Furthermore, the risk of developing CLL is 6 times...
4 Four years later, the FDA approved two autologous CAR-T cell therapies for patients with certain types of hematologic cancers: relapsed or refractory ALL and relapsed or refractory large B cell lymphoma. To date, autologous CAR-T therapies have received six approvals across five products. ...